What is the APS.TO share price today?

This page shows the latest available Aptose Biosciences Inc. (APS.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is Aptose Biosciences Inc. listed?

Aptose Biosciences Inc. trades on the Toronto Stock Exchange under the symbol APS.TO, ISIN CA03835T4081.

How large is Aptose Biosciences Inc.?

Its market capitalisation is approximately 6.13M CAD, based on the latest available price and share count from our data provider.

Toronto Stock Exchange (TSX) · APS.TO · ISIN CA03835T4081

Aptose Biosciences Inc.

No trading activity has been reported for this listing since July 3, 2026. It may be delisted, halted or inactive.

2.40 CAD

July 3, 2026

Aptose Biosciences Inc. (APS.TO) trades on the Toronto Stock Exchange and operates in the Biotechnology industry. Its market capitalisation is approximately 6.13M CAD. The company reports around 14 employees. Its ISIN is CA03835T4081. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Key facts

Exchange

Toronto Stock Exchange (TSX)

ISIN

CA03835T4081

Sector

Healthcare

Industry

Biotechnology

Country

Market cap

6.13M CAD

Employees

Previous close

2.40 CAD

Day range

2.40 – 2.40

52-week range

1.41 – 2.48

Volume

2.95K

50-day average

2.25 CAD

200-day average

2.14 CAD

Asset type

Equity

About Aptose Biosciences Inc.

Aptose Biosciences Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing personalized therapeutic solutions for challenging oncology cases, primarily within the United States. Its robust pipeline features several key clinical programs: APTO-253, currently in Phase 1a/b trials, targets patients with relapsed or refractory blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another candidate, HM43239, is undergoing Phase 1/2 evaluation for the treatment of relapsed or refractory AML. Aptose is also developing luxeptinib, which is in Phase 1a/b clinical studies for individuals battling relapsed or refractory B-cell malignancies, encompassing chronic lymphocytic leukemia, small lymphocytic lymphoma, various non-Hodgkin's lymphomas, as well as AML and HR MDS. Furthermore, the company is progressing with APL-581, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. Aptose maintains strategic alliances with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986 and headquartered in Toronto, Canada, the company was formerly known as Lorus Therapeutics Inc., changing its name to Aptose Biosciences Inc. in August 2014.

Company website

Frequently asked

What is the APS.TO share price today?: This page shows the latest available Aptose Biosciences Inc. (APS.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is Aptose Biosciences Inc. listed?: Aptose Biosciences Inc. trades on the Toronto Stock Exchange under the symbol APS.TO, ISIN CA03835T4081.
How large is Aptose Biosciences Inc.?: Its market capitalisation is approximately 6.13M CAD, based on the latest available price and share count from our data provider.

All Aptose Biosciences Inc. data comes from exchange and provider feeds for the Toronto Stock Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.